238 reports of this reaction
1.9% of all IVERMECTIN reports
#11 most reported adverse reaction
CONJUNCTIVAL HAEMORRHAGE is the #11 most commonly reported adverse reaction for IVERMECTIN, manufactured by Merck Sharp & Dohme LLC. There are 238 FDA adverse event reports linking IVERMECTIN to CONJUNCTIVAL HAEMORRHAGE. This represents approximately 1.9% of all 12,395 adverse event reports for this drug.
Patients taking IVERMECTIN who experience conjunctival haemorrhage should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CONJUNCTIVAL HAEMORRHAGE is a less commonly reported adverse event for IVERMECTIN, but still significant enough to appear in the safety profile.
In addition to conjunctival haemorrhage, the following adverse reactions have been reported for IVERMECTIN:
CONJUNCTIVAL HAEMORRHAGE has been reported as an adverse event in 238 FDA reports for IVERMECTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
CONJUNCTIVAL HAEMORRHAGE accounts for approximately 1.9% of all adverse event reports for IVERMECTIN, making it a notable side effect.
If you experience conjunctival haemorrhage while taking IVERMECTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.